Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in Oxford have begun screening participants in DPUK’s Deep and Frequent Phenotyping (DFP) study – the world’s most detailed study into early Alzheimer’s disease.

First participant arrives for screening as part of Deep and Frequent Phenotyping study
Study volunteer Gillian Brown talks to DFP trial co-ordinator Dr Tony Thayanandan

Launched last month, the DFP study is jointly funded by the MRC and NIHR, and aims to tackle the challenge of diagnosing and tracking Alzheimer’s disease in its earliest stages – often decades before symptoms start to show.

DFP will recruit 250 participants from across the UK who are over 60 and in good health, but with a family history of dementia. Volunteers will undergo a range of existing and novel tests over a year-long period, including brain scans, cognitive and memory tests, scans of brain magnetic fields, retinal imaging, blood tests, and the use of wearable technology to measure movement, gait and ongoing cognitive abilities.

This will be the most comprehensive set of assessments ever completed in this group of people. Data from the study will be made available to researchers via the secure DPUK Data Portal.

Read more (Dementias Platform UK website)

Similar stories

Five ways the pandemic has affected routine medical care

Since the beginning of the pandemic, COVID has infected at least a third of the UK population and is estimated to have factored in the deaths of almost 200,000 people in the UK. But critically, COVID has also had a devastating impact on our healthcare systems. While this was expected, new evidence is beginning to reveal the scope of the issue – in particular the effects for people living with long-term health conditions.

Clinical trials for a malaria vaccine start in Mali and Indonesia

Sanaria Inc. announced that two new Phase 2 trials of its pioneering malaria vaccines have started. The first is in 6- to 10-year-old children living in Bancoumana, Mali, a malarious region of West Africa. The second is in Indonesian soldiers based in Sumatra, Indonesia. The soldiers will be deploying for six to nine months this coming August to an intensely malarious district in eastern Indonesia.

Mechanism of expanding bacteria revealed

A new study published in Nature has identified a potential Achilles heel in the protective layers surrounding Gram-negative bacteria that could aid in the development of next-generation antibiotics.

Discovery of gene involved in chronic pain creates new treatment target

Oxford researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord, helping them to understand an important mechanism underlying chronic pain in humans and providing a new treatment target.

Oxford's largest ever study into Varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications establishes for the first time, a critical genetic risk score to predict the likelihood of patients suffering with Varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Biological processes of ageing is key to improving later life health

Improvements in health care, sanitation, and diet over last 100 years have significantly increased life expectancy. However, this increase in how long we can expect to live has not been accompanied by a similar increase in healthy life expectancy, defined as the time spent free of major illness or disease.